| Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128· 9 million … L Abarca-Gómez, ZA Abdeen, ZA Hamid, NM Abu-Rmeileh, ... The lancet 390 (10113), 2627-2642, 2017 | 7794 | 2017 |
| Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants B Zhou, Y Lu, K Hajifathalian, J Bentham, M Di Cesare, G Danaei, H Bixby, ... The lancet 387 (10027), 1513-1530, 2016 | 4110 | 2016 |
| Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19· 1 million participants B Zhou, J Bentham, M Di Cesare, H Bixby, G Danaei, MJ Cowan, ... The Lancet 389 (10064), 37-55, 2017 | 2685 | 2017 |
| Avian influenza A (H5N1) in 10 patients in Vietnam TT Hien, NT Liem, NT Dung, LT San, PP Mai, NV Chau, PT Suu, VC Dong, ... New England Journal of Medicine 350 (12), 1179-1188, 2004 | 1288 | 2004 |
| A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial JSG Montaner, P Reiss, D Cooper, S Vella, M Harris, B Conway, ... Jama 279 (12), 930-937, 1998 | 1006 | 1998 |
| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the … F Van Leth, P Phanuphak, K Ruxrungtham, E Baraldi, S Miller, B Gazzard, ... The Lancet 363 (9417), 1253-1263, 2004 | 886 | 2004 |
| Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study J Schouten, FW Wit, IG Stolte, NA Kootstra, M van der Valk, SE Geerlings, ... Clinical Infectious Diseases 59 (12), 1787-1797, 2014 | 846 | 2014 |
| Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia A Lazzarin, B Clotet, D Cooper, J Reynes, K Arastéh, M Nelson, ... New England Journal of Medicine 348 (22), 2186-2195, 2003 | 843 | 2003 |
| Dissemination of the mcr-1 colistin resistance gene MS Arcilla, JM van Hattem, S Matamoros, DC Melles, J Penders, ... The Lancet infectious diseases 16 (2), 147-149, 2016 | 583 | 2016 |
| Hypertension in Sub-Saharan Africa: Cross-Sectional Surveys in Four Rural and Urban Communities H ME, RMTL Wit FWNM, B LM, A TM, de Beer IH, M SG, K AM, G P, R GV, ... PLos One 12 (3), e 32638, 2012 | 510* | 2012 |
| The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years MR Nelson, C Katlama, JS Montaner, DA Cooper, B Gazzard, B Clotet, ... Aids 21 (10), 1273-1281, 2007 | 452 | 2007 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 438 | 2010 |
| HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study RL Hamers, CL Wallis, C Kityo, M Siwale, K Mandaliya, F Conradie, ... The Lancet infectious diseases 11 (10), 750-759, 2011 | 343 | 2011 |
| Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America Antiretroviral Therapy Cohort Collaboration Clinical Infectious Diseases 41 (12), 1772-1782, 2005 | 286 | 2005 |
| Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): a case-control study MO Owolabi, F Sarfo, R Akinyemi, M Gebregziabher, O Akpa, A Akpalu, ... The Lancet Global Health 6 (4), e436-e446, 2018 | 257 | 2018 |
| Mortality and progression to AIDS after starting highly active antiretroviral therapy AI van Sighem, MA van de Wiel, AC Ghani, M Jambroes, P Reiss, ... Aids 17 (15), 2227-2236, 2003 | 252 | 2003 |
| CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater L Gras, AM Kesselring, JT Griffin, AI Van Sighem, C Fraser, AC Ghani, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 45 (2), 183-192, 2007 | 251 | 2007 |
| Global phylogenetic analysis of Escherichia coli and plasmids carrying the mcr-1 gene indicates bacterial diversity but plasmid restriction S Matamoros, JM Van Hattem, MS Arcilla, N Willemse, DC Melles, ... Scientific reports 7 (1), 15364, 2017 | 249 | 2017 |
| Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a … RL Hamers, R Schuurman, KCE Sigaloff, CL Wallis, C Kityo, M Siwale, ... The Lancet infectious diseases 12 (4), 307-317, 2012 | 232 | 2012 |
| Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection M Van der Valk, EH Gisolf, P Reiss, F Wit, A Japour, GJ Weverling, ... Aids 15 (7), 847-855, 2001 | 231 | 2001 |
OLADIMEJI AKEEM BOLARINWAProfessor, Department of Epidemiology and Community Health, University of IlorinVerified email at unilorin.edu.ng
